PMV Pharmaceuticals, Inc.
NASDAQ:PMVPBiotechnology
+$0.04 today
- Market cap
- $65.06M
- Beta
- 1.36
- P/E (TTM)
- -0.8
- EPS (TTM)
- -$1.47
Volume 0.43M
Average 0.38M
PMVP Net Income
Bottom-line profit, the starting point for calculating cash from operations.
PMV Pharmaceuticals, Inc.NASDAQ: PMVP
Net Income · Q1 FY2026 · quarter ended Mar 2026
Net income grows, but more slowly than its trailing trend
Q1 FY2026 net income of $18.04M (cash outflow) rose 3.5% year over year, behind the +28.7% change in trailing-twelve-month net income. Sequentially, it rose 0.0% from the prior quarter. Over 3 fiscal years it compounded at +2.0% a year.
Context
- Net income grew in size in 1 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether net income reaches the consensus estimate from 3 analysts of -$76.89M (-1.1%) for the fiscal year ending Dec 2026, a slowdown from the +32.4% reported in FY2025.
Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$18.04M+0.0% QoQ
- Last fiscal yearDec 2025
- -$77.74M+32.4% YoY
- LTMMar 2026
- -$78.34M+28.7% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +3.5% | +0.6% | -2.9 pp |
| 1 year | +32.4% | -1.1% | -33.5 pp |
| 3-year CAGR | +2.0% | -13.1% | -15.1 pp |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Income history
USD · from the cash flow
- Latest · FY2025
- (77.74M) USD
- Year-over-year change
- -32.4%
| Period | Period end | Net Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (77.74M) | -32.4% |
| FY2024 | 2024-12-31 | (58.71M) | +14.9% |
| FY2023 | 2023-12-31 | (68.96M) | +5.9% |
| FY2022 | 2022-12-31 | (73.32M) | -26.7% |
| FY2021 | 2021-12-31 | (57.85M) | — |
Net Income vs competitors
How PMVP compares with its peers on the latest reported figures
- PMVP's LTM Mar 2026 net income of $78.34M is the 4th largest of the 9 companies compared; the peer median is $73.65M.
- Its year-over-year change of +28.7% is the 2nd highest of 9, against a peer median of -6.6%.
- Over three fiscal years its annual growth of +2.0% compares with a peer median of +17.8%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $124.31M | -5.5% | +25.1% | 1360.6% | |
| LTM Mar 2026 | $104.29M | +8.2% | -6.9% | — | |
CBUSCibus, Inc. | LTM Mar 2026 | $103.27M | -65.4% | +96.0% | 2409.4% |
| LTM Mar 2026 | $78.34M | +28.7% | +2.0% | — | |
ACRVAcrivon Therapeutics, Inc. Common Stock | LTM Mar 2026 | $77.27M | -7.7% | +35.7% | — |
| LTM Mar 2026 | $70.03M | +10.4% | +17.8% | 36859.5% | |
| LTM Mar 2026 | $58.88M | -22.2% | -28.5% | — | |
| LTM Mar 2026 | $44.95M | -65.1% | -8.9% | — | |
| LTM Mar 2026 | $37.1M | +163.8% | — | 14.5% | |
| Peer median (excluding PMVP) | $73.65M | -6.6% | +17.8% | 1885.0% | |
Competitors are the stored peer set for PMVP. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (57.85M) | (73.32M) | (68.96M) | (58.71M) | (77.74M) |
| Depreciation & Amortization | 1.28M | 650K | 1.26M | 1.14M | 133K |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 5.34M | 10.2M | 12.38M | 8.87M | 5.92M |
| Change in Working Capital | 4.12M | (568K) | 5.43M | (1.59M) | 914K |
| Accounts Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 191K | (389K) | 235K | 3.34M | (3.42M) |
| Other Working Capital | 3.93M | (179K) | 5.19M | (4.93M) | 4.34M |
| Other Non-Cash Items | 5.87M | 9.48M | (5.76M) | (997K) | (2.81M) |
| Operating Cash Flow | (46.57M) | (63.76M) | (55.66M) | (51.28M) | (73.58M) |
| Capital Expenditures | (1.35M) | (7.98M) | (962K) | (655K) | (29K) |
| Acquisitions (Net) | 0 | 0 | 0 | 251K | 31K |
| Purchases of Investments | (256.85M) | (229.2M) | (220.54M) | (148.29M) | (88.2M) |
| Sales of Investments | 114.61M | 235.82M | 170.96M | 202.04M | 158.37M |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | (143.58M) | (1.37M) | (50.55M) | 53.35M | 70.17M |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | 2.02M | 958K | 35.12M | 313K | 505K |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 0 | 0 | 456K | 0 | 0 |
| Financing Cash Flow | 2.02M | 958K | 35.58M | 313K | 505K |
| Effect of Forex Changes | 1 | 0 | 34K | (35K) | 7K |
| Net Change in Cash | (188.13M) | (64.17M) | (70.59M) | 2.35M | (2.89M) |
| Free Cash Flow | (47.92M) | (71.74M) | (56.62M) | (51.94M) | (73.61M) |
PMV Pharmaceuticals, Inc.
NASDAQ:PMVP
Intrinsic Alpha fair value
Locked
Current Price
$1.22
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.